Surely You Joust
Executive Summary
Chiron's and Roche's press releases announcing a decision by the European Patent Office's Technical Board of Appeals regarding HCV patents made it sound like the companies were attending different hearings and discussing different subject matter. They epitomize the brinksmanship the two are playing over the nucleic acid testing (NAT) market.